Q-omics provides the consensus-scored YTHDF2 profile across patient tissues and cancer cell-line models. YTHDF2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, YTHDF2 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, YTHDF2 protein abundance shows 25,417 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, BLCA, and GBM as cancer lineages where YTHDF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YTHDF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YTHDF2 survival associations across molecular data types. YTHDF2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YTHDF2 RNA expression–survival associations across cancer types. High YTHDF2 expression shows unfavorable associations in LIHC, ACC, LGG, KICH and CESC, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for YTHDF2 RNA expression.
This table summarizes YTHDF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for YTHDF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YTHDF2 shows lower tumor expression in KICH and higher tumor expression in BLCA, STAD, LIHC, HNSC and CHOL. The BLCA box plot shows higher YTHDF2 RNA expression in tumor versus normal tissue (log2 FC = +0.531, t-test p = .001).
This table shows molecular features associated with YTHDF2 in patient tissues and cancer cell lines. In patient samples, YTHDF2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, YTHDF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
